At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 30, 2026 at 16:06 ET
Xeris Biopharma announced routine board governance changes: CEO John Shannon was appointed Chair of the Board, Marla Persky transitioned to Lead Independent Director, and Nerissa Kreher, M.D., was added as an independent director. The board expanded from seven to eight members. No financial data or operational updates were provided.
- Board expanded from 7 to 8 members with the appointment of Nerissa Kreher, M.D., effective July 1, 2026
- CEO John Shannon appointed Chair of the Board, effective July 1, 2026
- Marla Persky designated as Lead Independent Director, effective July 1, 2026
- Dr. Kreher received an initial equity award with aggregate grant date fair value of approximately $450,000
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access